|
|
|
For other announcements of interest to the medical community, choose a subcategory from the menu on the left.
|
|
|
|
|
An IMF Webcast that addresses frequently asked questions about kyphoplasty: Who is a good candidate? What clinical outcomes are you looking for? Can a patient receive kyphoplasty while undergoing chemo? How quickly have patients reported pain relief after the procedure. |
|
|
|
|
The Working Group, made up of 90 leading myeloma researchers, develops myeloma management guidelines aimed at providing patients with more durable remissions and a better quality of life. The Working Group's recent research has culminated in the publication of widely-used consensus statements. |
|
|
|
|
Summaries from the workshop sessions in Kos, Greece on 5–30 June, 2007 |
|
|
|
|
Webcast of the Friday Satellite Symposium Preceding the 49th ASH Annual Meeting. |
|
|
|
|
We are pleased to present these webcasts of the 49th Annual American Society of Hematology Meeting (ASH) that was held in Atlanta, Georgia from December 8-11, 2007. |
|
|
|
|
|
Established by the International Myeloma Foundation, the U.S. Myeloma Forum is a committee of the nation’s leading multiple myeloma experts. The Forum’s goal is two-fold: to form a coalition that will work collaboratively on myeloma-related projects, and to avoid duplication of efforts and dilution of valuable resources by various cooperative groups working on myeloma trials in the United States. |
|
|
|
|
|
BANK ON A CURE® DNA Data Base also finds Genetic Link to Bone Disease and Indications for Treatment |
|
|
|
|
|
Survival and Longer Term Disease Control Take Precedence over Short Term Response to Treatment |
|
|
|
|
|
A new ASCO Clinical Practice Guideline, "Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer," is now available, along with clinical tools and resources to help practicing oncologists and their colleagues implement the evidence-based recommendation in clinical settings. |
|
|
|
|
|
Emerging safety concerns (thrombosis, cardiovascular events, tumor progression, and reduced survival) derived from clinical trials in several cancer and non-cancer populations prompted CMS to review its coverage of erythropoiesis stimulating agents (ESAs). |
|
|
print
back to top